JAMA Cardiol

HFSA 2024: Mavacamten shows promise in heart failure

October 3, 2024

Mavacamten treatment led to significant reductions in cardiac stress biomarkers and improvements in heart function in patients with heart failure with preserved ejection fraction (HFpEF) and left ventricular ejection fraction (LVEF) ≥60%. The findings were shared at the recent Heart Failure Society of America meeting.

The EMBARK-HFpEF trial, a phase 2a, open-label, single-arm study, was conducted at 20 sites in the U.S. and Canada from November 2020 to February 2024. A total of 30 participants (median age, 76 years; 53.3% female) received mavacamten for 26 weeks, starting at 2.5 mg and potentially increasing to 5 mg at week 14 based on prespecified LVEF and NTproBNP criteria.

Key findings

Mavacamten treatment resulted in a 26% reduction in NTproBNP, a 13% reduction in high-sensitivity troponin T, and a 20% reduction in high-sensitivity troponin I from baseline to week 26. Cardiac biomarker values returned toward baseline levels 8 weeks after drug discontinuation. Mean LVEF decreased by 3.2 percentage points during treatment, but no sustained reductions in LVEF were observed.

Source:

Shah SJ, et al. (2024, September 30). JAMA Cardiol. Cardiac Myosin Inhibition in Heart Failure With Normal and Supranormal Ejection Fraction: Primary Results of the EMBARK-HFpEF Trial. https://pubmed.ncbi.nlm.nih.gov/39347697/